Navigation Links
InfuSystem Pays Down Term Loan by $6.1 Million Year-to-Date
Date:4/8/2009

MADISON HEIGHTS, Mich., April 8 /PRNewswire-FirstCall/ -- InfuSystem (OTC Bulletin Board: INHI; INHIW; INHIU), the leading provider of ambulatory infusion pumps and associated clinical services, today announced that it has made a $5.3 million payment on its Term Loan in addition to its normal quarterly $818,000 payment. As a result of the combined payments year-to-date, InfuSystem has reduced the total amount outstanding on its Term Loan by $6.1 million, to $24.1 million. The Term Loan was a result of the sale of InfuSystem, Inc. from its former parent company, completed in October 2007.

Mr. Steve Watkins, Chief Executive Officer, commented, "InfuSystem continues to generate strong free cash flow, which has enabled us to rapidly pay down our Term Loan. The Term Loan originally stood at $32.7 million as of October 2007, and in less than 18 months, we have reduced the principal amount due by over $8.5 million. We plan to continue aggressively paying down this loan, while maintaining a solid cash position on our balance sheet."

About InfuSystem Holdings, Inc.

InfuSystem is the leading provider of ambulatory infusion pumps and associated clinical services for oncology practices and their patients in the U.S. These pumps allow for the gradual delivery of a drug over a period of days in the privacy of one's home, compared to bolus infusion chemotherapy treatments that are given in a single high dose over a short period of time. Improved efficacy of the drugs, patient comfort, reimbursement to doctors for appropriate services and continuity of care all play a role in the growing trend toward this form of treatment. InfuSystem's pumps are primarily used for colorectal cancer, but they have been approved for other forms of cancer, thereby greatly enhancing the market opportunity for InfuSystem.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. These risks and uncertainties include general economic conditions, as well as other risks detailed from time to time in InfuSystem's publicly filed documents.


'/>"/>
SOURCE InfuSystem Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. InfuSystem Holdings Reports 12.9% Revenue Increase and $3.3 Million of Adjusted EBITDA for the Fourth Quarter of 2008
2. InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results
3. InfuSystem Holdings Appoints Two New Board Members
4. ORTHOCON Announces Appointment of New CEO and $25 Million Series B Financing
5. Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017
6. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
7. Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses
8. The Healy Law Firm Represents Plaintiff in $12 Million Settlement with Clark USA Over Fatal Illinois Oil Refinery Accident
9. Siemens Financial Services, Inc. Provides $29.5 Million Credit Package to Avanti Health System
10. Partnership for Prescription Assistance Celebrates Four-Year Anniversary; Helps More Than 5.7 Million Uninsured Patients Across United States
11. Harris Corporation Awarded $14 Million Contract to Develop Multi-Hospital Military Health System Network with Image-Sharing Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with the ... study from the Osteoarthritis Initiative shows that certain people who experience consistent ... in advance may give doctors the opportunity to treat patients before the problem becomes ...
(Date:5/26/2017)... Texas (PRWEB) , ... May 26, 2017 , ... Amir ... Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS ... , “We are pleased to be the first in Arkansas to introduce the most ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the Congressional Budget Office ... U.S. House on May 4, would result in 23 million Americans losing their health ... the 2010 Patient Protection and Affordable Care Act (ACA). , “It is clear ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon ... informational blog post on insurance options. If a Bay Area patient has to search ... time and money. Visiting an in-network provider for a second opinion can ensure a ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: the ... others. “Cactus Jack: Against All Odds” is the creation of published author, Walter ... is married to Jack Carlisle’s third child Jane. Walter. Walter and Jane have ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... , May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: ... approximately 100,000 square feet to its Welch Allyn campus. ... its commitment to bring more than 100 new jobs ... Welch Allyn has maintained a significant presence for more ... these new positions, a large portion of which will ...
(Date:5/4/2017)...  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... today announced that it is teaming up with Auto ... to lower diabetes healthcare costs in Canada ... is available throughout all provinces and territories in ... for additional savings when shopping for Dario supplies in ...
(Date:5/3/2017)...  Getinge, a leading global provider of products ... cost efficiency within healthcare and life sciences, today ... demonstrating that intra-aortic balloon counterpulsation (IABC) appears effective ... The single-center, retrospective, observational study showed that use ... 50cc intra-aortic balloon (IAB) in contemporary practice ...
Breaking Medicine Technology: